Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Artificial intelligence may help decide who gets a liver first

NCT ID NCT06723275

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This study tests whether artificial intelligence can more accurately predict which patients on the liver transplant waiting list are at highest risk of dying or becoming too sick for surgery. Researchers will follow 630 adults with severe liver disease or liver cancer across five European countries, collecting blood, urine, and tissue samples along with detailed health data. The goal is to validate new AI-based models that could eventually replace current scoring systems and improve how donor livers are allocated.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to fairer and more accurate systems for allocating donor livers to the patients who need them most urgently.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly help participants. The AI models may not prove more accurate than current methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 630 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients consecutively listed for LT for end-stage chronic liver diseases and HCC

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult \[age 18;70\] patients listed for: * decompensated cirrhosis as primary diagnosis, irrespective of liver disease etiology (subset1) OR * other end-stage liver diseases requiring LT, listed under MELD offering schemes (subset 2), including notably but not exclusively cholestatic diseases, primary biliary cholangitis, primary sclerosing cholangitis (subset 2) OR * HCC as primary diagnosis, whatever the etiology of the underlying liver disease with or without underlying cirrhosis (subset 3). (HCC diagnosed on Barcelona/EASL criteria or histologically proven. HCC meeting or not Milan criteria, as per center practice.) * Patients registered on national waiting lists under the MELD offering schemes, regardless of extra MELD points are affected or not. * Patient (or trusted person, family member or close relation, if the patient is unable to express consent) who has been informed and signed the informed consent. * Patient affiliated with a health insurance scheme (beneficiary or entitled party). Exclusion Criteria: * Tumor vascular invasion (portal or hepatic veins) evidenced by imaging on pre transplantation work-up, including PVT stage 1 * Extra-hepatic metastasis of HCC, as assessed by sectional imaging, functional imaging (18 FDG PET CT/MRI) or histologically proven * Women who are pregnant or nursing * Patients who are under safeguard of justice or tutorship or curatorship * Patient on AME (state medical aid) * Participation in another trial including other studies proposed as part of the European LEOPARD project (cohort associated to WP1 \& WP5 ("LEOPARD TVDCS") or being in the exclusion period following previous interventional research involving the human person, if applicable

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Decompensated liver cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cholangitis, Sclerosing chronic liver failure cirrhosis of liver hepatocellular carcinoma primary biliary cholangitis primary sclerosing cholangitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Decompensated liver cirrhosis Hepato-cellular carcinoma Primary biliary cholangitis Primary sclerosing cholangitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beaujon Hospital, Department of Hepatology

    RECRUITING

    Clichy, France, 92110, France

  • Center for Liver Tumors Leiden of the Leiden University Medical Center (LUMC)

    NOT_YET_RECRUITING

    Leiden, Netherlands, Netherlands

  • Department of Gastroenterology and Hepatology Universitair Ziekenhuis Gent

    NOT_YET_RECRUITING

    Ghent, Belgium, Belgium

  • Hospital Henri Mondor, Department of Hepatology

    RECRUITING

    Créteil, France, 94010, France

  • Hospital La Pitié Salpêtrière, Department of Hepato-gastro-enterology

    RECRUITING

    Paris, France, 75013, France

  • Italian National Transplant Center

    NOT_YET_RECRUITING

    Roma, Italy, Italy

  • St Eloi Hospital, Department of Hepato-gastro-enterology,

    RECRUITING

    Montpellier, France, 34295, France

  • Universitätsklinikum Schleswig - Holstein | UKSH · Transplantation Medicine

    NOT_YET_RECRUITING

    Kiel, Germany, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.